SANA
Sana Biotechnology Inc (SANA)
Healthcare • NASDAQ • $3.51+0.29%
- Symbol
- SANA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $3.51
- Daily Change
- +0.29%
- Market Cap
- $947.67M
- Trailing P/E
- N/A
- Forward P/E
- -6.61
- 52W High
- $6.55
- 52W Low
- $1.60
- Analyst Target
- $8.57
- Dividend Yield
- N/A
- Beta
- 2.18
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreem…
Company websiteResearch SANA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.